कृपया अन्य खोज का प्रयास करें
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company’s lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
James F. Oliviero | 46 | 2015 | President, CEO & Director |
Barry M. Salzman | 60 | 2016 | Independent Director |
Michael S. Weiss | 56 | 2015 | Chairman of the Board |
Neil Herskowitz | 65 | 2015 | Independent Director |
Wayne A. Marasco | 68 | 2015 | Chairman of Scientific Advisory Board |
Lindsay Allan Rosenwald | 67 | 2014 | Non-Executive Director |
Emily Ruiz | - | 2021 | Member of Scientific Advisory Board |
David Miller | - | 2021 | Member of Scientific Advisory Board |
Christian M. Béchon | 65 | 2018 | Independent Director |
F. Stephen Hodi | - | 2021 | Member of Scientific Advisory Board |
Bruce E. Johnson | - | 2021 | Member of Scientific Advisory Board |
Roy Steven Herbst | 61 | - | Member of Scientific Advisory Board |
Amit Sharma | - | 2024 | Independent Non-Executive Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है